RENEW-OP-1
About
Brenipatide is a dual GIP and GLP-1 that may play a role in the adjunctive treatment of opioid use disorder by helping to maintain abstinence and reduce the risk of opioid relapses and overdose. This study will investigate the effects of brenipatide across a wide dose range to inform further clinical development of the molecule for the treatment of OUD.
Eligibility Criteria
Inclusion Criteria
- 18 to 75 years of age
- Have a diagnosis of OUD
- Taking transmucosal buprenorphine
- Willing to comply with all study assessments and procedures
Exclusion Criteria
- Diagnosed schizophrenia, bipolar disorder, borderline personality disorder, or eating disorder
- Opioid overdose in past 6 months
- Current substance use disorder (excluding OUD)
- Pregnant or breastfeeding or planning to become pregnant/breastfeed
Contact Information
Abigail Crawford
Clinical Research Coordinator
Principal Investigator
Dr. Albert Arias is a psychiatrist with over 25 years of clinical and research experience. He is a professor at the Virginia Tech Carilion School of Medicine. He is board certified by American Board of Psychiatry and Neurology in Psychiatry. He completed his residency at the University of Connecticut Health.